Tonix Pharmaceuticals Holding Corp. 8-K

What Happened
Tonix Pharmaceuticals Holding Corp. announced that at its annual meeting on May 7, 2026, shareholders approved the company's 2026 Stock Incentive Plan. The plan, described in the company’s definitive proxy statement filed March 30, 2026 under “Proposal No. 4,” authorizes the grant of various equity-based awards to employees, directors and key consultants of Tonix and its subsidiaries. The full text of the plan is incorporated by reference (Exhibit 10.01 / Annex A to the proxy).

Key Details

• Approval date: May 7, 2026 (Annual Meeting of Shareholders).
• Disclosure: Plan terms summarized in the Definitive Proxy Statement filed March 30, 2026.
• Scope: Authorizes grants of various equity-based incentive awards to employees, directors and key consultants of Tonix and its subsidiaries.
• Exhibit: 2026 Stock Incentive Plan filed as Exhibit 10.01 and incorporated by reference.

Why It Matters
A shareholder-approved stock incentive plan gives Tonix flexibility to grant stock options, restricted stock, RSUs or similar awards to recruit and retain talent and to compensate management. Such plans can increase share-based compensation expense and may be dilutive to existing shareholders depending on the number of shares authorized and issued. Investors should review the March 30, 2026 proxy (and the full plan text in Exhibit 10.01) for the specific share pool, award limits and other terms to assess potential dilution and impact on earnings and ownership.